Drugs /

m8891

Back to Drugs List

Overview

NCI Definition [1]:
A proprietary orally available inhibitor of methionine aminopeptidase 2 (MetAP2), which cleaves the amino-terminal methionine residue from nascent proteins, with potential antiangiogenic and antineoplastic activities. Upon administration, MetAP2 inhibitor M8891 inhibits MetAP2 aminopeptidase activity and impairs protein synthesis, which may lead to a decrease in endothelial cell proliferation. Decreased proliferation of endothelial cells results in reductions of both angiogenesis and the growth and spread of solid tumors that are dependent on new blood vessel formation. MetAP2, a metallopeptidase, is involved in promoting protein synthesis and endothelial cell proliferation.

Clinical Trials

View Clinical Trials for m8891

M8891 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating m8891, 1 is phase 1 (1 open).

Clear cell renal cell carcinoma and malignant solid tumor are the most common diseases being investigated in m8891 clinical trials [2].

Drug Details

Synonyms [2]:
metap2 inhibitor m8891, methionine aminopeptidase 2 inhibitor m8891
Drug Target(s) [2]:
METAP2
NCIT ID [1]:
C142831

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.